Solid tumor targeted NGS panel

Alphabetical Test listing

Solid tumor targeted NGS panel-Pathology add-on

Solid tumor targeted NGS panel
Pathology add-on
Hot spot mutations
Next Generation Sequencing
Oncomine focus assay

52 genes


Next Generation Sequencing (NGS) for the detection of alterations in solid tumors is critical for cancer care as these findings can direct the optimal use of targeted therapies for patients.


If blocks more than 5 years old are submitted for testing, extraction will be attempted, but if insufficient RNA/DNA is retrieved, testing will be cancelled

Tumor tissue

Formalin-fixed paraffin-embedded (FFPE) tissue block


Cytology slide


Molecular Medicare billing request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.

  • Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
  • All information requested is required in order for your request to be completed


  • Improper label (unlabeled or mislabeled)
  • Improper storage
  • Interfering substances
  • Slides broken beyond repair
AHL - Molecular Diagnostics: D
10 business days

Next Generation Sequencing


No variations detected

This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
81455 - NGS: targeted genomic sequence analysis panel, solid organ 51 or greater genes